DUBLIN--(BUSINESS WIRE)--The "Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.
Biologics constitute a majority of the top selling drugs of today and also represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical market has increased from 16% in 2006 to over 25% in 2017. Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion. Despite their clinical and commercial success, biopharmaceutical products are associated with high development costs, which are evidently reflected in their prices.
Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous delivery options are being investigated for various clinical candidates across different phases of development. In fact, several approved therapeutic products that are currently delivered intravenously are also being reformulated and evaluated for subcutaneous administration in order to improve their adoption, and for life cycle management of drugs nearing patent expiry.
In addition, several drug delivery devices that can be used for self-administration have been developed, and many others are under development. Some of the most popular self-administration enabling devices include large volume wearable injectors, autoinjectors, pen injectors, needle free injectors and prefilled syringes.
Companies Mentioned
- 3D Medicines
- AB2 Bio
- Abbott Laboratories
- AbbVie
- Ablynx
- AC Immune
- Acceleron Pharma
- Accord Healthcare
- Acer Therapeutics
- ACG Management
- Adisave
- Adocia
- Anthera Pharmaceuticals
- Aphios
- Apobiologix
- Baxalta
- Bay City Capital
- Bayer
- Bespak
- Bill & Melinda Gates Foundation
- Bioam Gestion
- BioAtla
- Cam Med
- Cambridge Antibody Technology
- Elektrofi
- Eli Lilly
- EMD Serono
- Emergent BioSolutions
- Emperra
- Enable Injections
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Subcutaneous Biologics: Current Market Landscape
5. Subcutaneous Biologics: Case Studies of Leading Products
6. Subcutaneous Formulation Technologies: Current Market Landscape
7. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis
8. Subcutaneous Formulation Technology Providers: Company Profiles
9. Subcutaneous Drug Delivery Systems: Current Market Landscape
10. Market Forecast and Opportunity Analysis
11. SWOT Analysis
12. Conclusion
13. Executive Insights
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and Organizations
For more information about this report visit https://www.researchandmarkets.com/research/s2qfjz/subcutaneous?w=4
